Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease

The development of immune checkpoint inhibitors (ICI) has dramatically changed the clinical management of metastatic melanoma and other solid tumors. Despite exclusion from initial clinical trials, there is a growing body of retrospective data that suggest ICI can be used in patients with underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietz, Hilary, Weinmann, Sophia C, Salama, April K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572012/
https://www.ncbi.nlm.nih.gov/pubmed/34754240
http://dx.doi.org/10.2147/CMAR.S283217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572012/
https://www.ncbi.nlm.nih.gov/pubmed/34754240
http://dx.doi.org/10.2147/CMAR.S283217

Ejemplares similares